The biopharmaceutical industry faces increasing pressure for innovative treatments, yet the transformation through artificial intelligence (AI) is slower than anticipated. While AI is being utilized to enhance drug development and streamline clinical trials—reducing timelines by up to 10X—traditional processes must adapt more swiftly to meet rising global demands and regulatory challenges. The article emphasizes the urgent need for the industry to fully leverage AI's potential.
